Reports for GE HEALTHCARE CANADA INC
Company Name
GE HEALTHCARE CANADA INC
Totals |
||
Shortage reports |
69 |
|
| Actual shortage: | 1 (1%) | |
| Anticipated shortage: | 0 (0%) | |
| Avoided shortage: | 5 (7%) | |
| Resolved: | 63 (91%) | |
Discontinuation Reports |
5 |
|
| To be discontinued: | 1 (20%) | |
| Discontinued: | 4 (80%) | |
| Reversed: | 0 (0%) | |
Late reports |
0 (0%) |
|
Overdue reports |
0 (0%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| OMNIPAQUE 240 | 518MG | SOLUTION | Actual shortage | 2022-05-13 | 2023-03-23 | 160528 |
| INDIUM DTPA IN 111 | 37MBq | SOLUTION | Resolved | 2023-03-03 | 2023-03-18 | 186110 |
| OMNIPAQUE 240 | 518MG | SOLUTION | Resolved | 2022-05-13 | 2023-03-01 | 160525 |
| OMNIPAQUE 300 | 647MG | SOLUTION | Resolved | 2022-05-12 | 2023-03-01 | 160389 |
| VISIPAQUE 270 | 550MG | SOLUTION | Resolved | 2022-06-03 | 2023-02-07 | 161852 |
| VISIPAQUE 320 | 652MG | SOLUTION | Resolved | 2022-05-13 | 2023-01-31 | 160519 |
| VISIPAQUE 270 | 550MG | SOLUTION | Resolved | 2022-05-27 | 2023-01-30 | 161445 |
| OMNIPAQUE 240 | 518MG | SOLUTION | Avoided shortage | 2022-11-30 | 2023-01-25 | 176387 |
| OMNIPAQUE 180 | 388MG | SOLUTION | Resolved | 2022-12-14 | 2023-01-20 | 178377 |
| OMNIPAQUE 300 | 647MG | SOLUTION | Resolved | 2022-05-13 | 2023-01-17 | 160537 |
| OMNIPAQUE 300 | 647MG | SOLUTION | Resolved | 2022-05-13 | 2023-01-17 | 160562 |
| OMNIPAQUE 350 | 755MG | SOLUTION | Resolved | 2022-05-13 | 2023-01-17 | 160543 |
| OMNIPAQUE 240 | 518MG | SOLUTION | Resolved | 2022-05-13 | 2023-01-11 | 160531 |
| OMNIPAQUE 300 | 647MG | SOLUTION | Resolved | 2022-05-13 | 2023-01-07 | 160534 |
| VISIPAQUE 270 | 550MG | SOLUTION | Resolved | 2022-05-13 | 2023-01-05 | 160506 |
| VISIPAQUE 270 | 550MG | SOLUTION | Resolved | 2022-05-27 | 2023-01-05 | 161439 |
| VISIPAQUE 320 | 652MG | SOLUTION | Resolved | 2022-05-13 | 2023-01-05 | 160510 |
| VISIPAQUE 320 | 652MG | SOLUTION | Resolved | 2022-05-13 | 2023-01-05 | 160513 |
| VISIPAQUE 320 | 652MG | SOLUTION | Resolved | 2022-05-13 | 2023-01-05 | 160516 |
| OMNIPAQUE 300 | 647MG | SOLUTION | Resolved | 2022-05-13 | 2023-01-05 | 160540 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| OMNIPAQUE 240 | 518MG | SOLUTION | Discontinued | 2023-01-31 | 2023-03-18 | 182760 |
| OMNIPAQUE 180 | 388MG | SOLUTION | Discontinued | 2023-01-31 | 2023-02-22 | 182757 |
| OMNISCAN | 287MG | SOLUTION | To be discontinued | 2023-01-31 | 2023-01-31 | 182742 |
| THALLOUS CHLORIDE TI 201 INJECTION | 37MBq | SOLUTION | Discontinued | 2020-12-04 | 2021-06-05 | 129592 |
| Metastron | 37 MBq/mL | Solution | Discontinued | 2018-10-12 | 2019-02-01 | 63929 |
Showing 1 to 5 of 5